JAMA Netw Open

Influencer-driven drug promotion raises red flags in systematic review

March 25, 2026

A systematic scoping review published in JAMA Network Open highlights substantial risks associated with prescription drug promotion by social media influencers. Reviewing 12 studies from more than 3,500 screened records, researchers found consistent themes of misinformation, weak regulatory oversight, and inconsistent or absent disclosure of paid promotion. Influencers often shared emotionally resonant personal stories that blurred the line between authentic experience and marketing intent, amplifying the persuasive impact of incomplete or inaccurate claims. Examples included overstated drug benefits, omission of risks or alternative treatments, and promotion that FDA later deemed misleading. The review also noted that platform algorithms may elevate such content in largely unmonitored environments, further complicating FDA and FTC enforcement.

Clinical takeaway: Counsel patients that drug information encountered through influencers may be inaccurate or incomplete; encourage reliance on verified clinical sources and reinforce the importance of discussing treatment decisions directly with healthcare professionals.

Source:

Gell S, et al. (2026, March 23). JAMA Netw Open. Prescription Drug Promotion by Social Media Influencers: A Systematic Scoping Review. https://pubmed.ncbi.nlm.nih.gov/41870429/